Pulmonx Corporation (LUNG)
NASDAQ: LUNG · IEX Real-Time Price · USD
6.45
-0.35 (-5.22%)
At close: Jun 11, 2024, 4:00 PM
6.49
+0.04 (0.70%)
After-hours: Jun 11, 2024, 4:19 PM EDT

Pulmonx Revenue

Pulmonx had revenue of $72.99M in the twelve months ending March 31, 2024, with 27.14% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $18.85M with 29.71% year-over-year growth. In the year 2023, Pulmonx had annual revenue of $68.68M with 27.98% growth.

Revenue (ttm)
$72.99M
Revenue Growth
+27.14%
P/S Ratio
3.51
Revenue / Employee
$261,627
Employees
279
Market Cap
250.17M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202368.68M15.01M27.98%
Dec 31, 202253.66M5.25M10.84%
Dec 31, 202148.42M15.68M47.91%
Dec 31, 202032.73M138.00K0.42%
Dec 31, 201932.60M12.59M62.94%
Dec 31, 201820.00M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
AngioDynamics 324.01M
Amarin Corporation 277.46M
Poseida Therapeutics 82.50M
Enanta Pharmaceuticals 72.88M
Nanobiotix 40.23M
Mersana Therapeutics 38.30M
uniQure 19.00M
Adaptimmune Therapeutics 18.36M
Revenue Rankings